| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Matinas BioPharma Holdings, Inc. | Director | Stock Option (right to Buy) | 11,600 | 30 Apr 2025 | Direct | ||
| Grace Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 10,000 | 08 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GRCE | Grace Therapeutics, Inc. | 08 Jan 2026 | 1 | $0 | 4 | Director | 12 Jan 2026, 16:01 |
| GRCE | Grace Therapeutics, Inc. | 09 May 2025 | 1 | $0 | 4 | Director | 13 May 2025, 17:21 |
| MTNB | Matinas BioPharma Holdings, Inc. | 30 Apr 2025 | 1 | $0 | 4 | Director | 02 May 2025, 17:19 |
| MTNB | Matinas BioPharma Holdings, Inc. | 11 Mar 2025 | 0 | $0 | 3 | Director | 17 Mar 2025, 17:30 |
| GRCE | Acasti Pharma Inc. | 19 Dec 2023 | 1 | $0 | 4 | Director | 20 Dec 2023, 16:06 |
| GRCE | Acasti Pharma Inc. | 10 Oct 2023 | 0 | $0 | 3 | Director | 20 Oct 2023, 12:22 |